Cost-Effectiveness of Nivolumab Plus Cabozantinib Versus Sunitinib as a First-Line Treatment for Advanced Renal Cell Carcinoma in the United States

Background: In a recent randomized, phase 3 trial (CheckMate 9ER), nivolumab combined with cabozantinib significantly improved patient outcomes compared with sunitinib. However, the cost-effectiveness of these novel agents for untreated advanced renal cell carcinoma (aRCC) remains unknown. Materials...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, SiNi, Li, JianHe, Peng, LiuBao, Li, YaMin, Wan, XiaoMin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8711761/
https://www.ncbi.nlm.nih.gov/pubmed/34966275
http://dx.doi.org/10.3389/fphar.2021.736860

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8711761/
https://www.ncbi.nlm.nih.gov/pubmed/34966275
http://dx.doi.org/10.3389/fphar.2021.736860

Ejemplares similares